Clinical trials regulation--how Canada compares

Shuchman, Miriam
September 2008
CMAJ: Canadian Medical Association Journal;9/23/2008, Vol. 179 Issue 7, p635
Academic Journal
journal article
The article reports on the safety of clinical trials after the incidence of a 48-year-old man with no history of cardiac problems suffered two heart attacks and died during a testing of a new drug. The Medicine and Healthcare Products Regulatory Agency of Great Britain conducted an investigation regarding the anomalous death. Due to the incident, Great Britain and U.S. were forced to reform their system of clinical trials. For two years, Health Canada has been reviewing its clinical trials regulatory framework but restructuring proposals for the system have been reported. INSET: Canada lags the United States in transparency of clinical....


Related Articles

  • Use of herbal medicines. Newson, Louise // GP: General Practitioner;3/16/2007, p46 

    The article reports on the status of herbal medicine in Great Britain. Legally, herbal products are classified as food supplements and are widely available from health food shops and chemists. For most herbal treatments trials of efficacy are lacking. In Great Britain, the Medicines and...

  • HIV drugs made in tobacco. Fox, Jeffrey L // Nature Biotechnology;Oct2011, Vol. 29 Issue 10, p852 

    The article reports that the British Medicines and Healthcare Products Regulatory Agency has approved the phase 1 clinical trial of Pharma-Planta's human monoclonal antibody made in genetically modified tobacco plants for preventing human immunodefiency virus (HIV) spread between sexual partners.

  • Health Canada issues foreign product alerts.  // Reactions Weekly;5/10/2008, Issue 1201, p3 

    The article reports on the warning of Health Canada regarding the use of Tian Li or Xian Zhi Wei II due to their adverse effects. Great Britain's Medicines and Healthcare products Regulatory Agency (MHRA) states that Tian Li is said to have tadalafil and hydroxyhomosildenafil which are not...

  • Pharmacovigilance & Regulatory News.  // Reactions Weekly;1/20/2007, Issue 1135, p2 

    The article offers regulatory news on pharmacology. A Foreign Product Alert was issued by Health Canada to warn that Qing Zhi along with one unlabelled product were found to be adulterated with sibutramine. The British Medicines & Healthcare Products Regulatory Agency is warning against the use...

  • Pharmacovigilance & Regulatory News.  // Reactions Weekly;7/26/2008, Issue 1212, p2 

    This section offers news briefs on issues related to pharmacovigilance. Neurogen Corp. has suspended a clinical trial investigating the treatment of insomnia with a bilayer tablet formulation of adipiplon due to a higher rate of unwanted next day effects. The Canadian government is planning to...

  • Tanning drug risky, British regulators warn.  // Dermatology Times;Feb2009, Vol. 30 Issue 2, p31 

    The article reports on a warning issued by Great Britain's Medicines and Healthcare Regulatory Agency concerning the use of tanning drugs. The agency issued a warning about the dangers of using the synthetic hormone Melanotan. A report claimed that Melanotan is unlicensed in Great Britain and...

  • Northwest's DCVax-L Adds UK Sites in Phase III GBM Program. Shaffer, Catherine // BioWorld Today;8/24/2012, Vol. 23 Issue 165, p1 

    The article reports on the 300-patient Phase III trial of Bethesda, Maryland-based Northwest Biotherapeutics Inc.'s DCVax-L for glioblastoma multiforme (GBM), approved by the Great Britain Medicines and Healthcare Products Regulatory Agency. It describes the composition of the product and the...

  • 'Special Exemptions': Should They Be Put on Trial? Gaspar, H Bobby; Swift, Sue; Thrasher, Adrian J // Molecular Therapy;Feb2013, Vol. 21 Issue 2, p261 

    The authors reflect on the implementation of special exemption schemes for the use of experimental therapeutics in Europe. They outline the role of the Medicines and Healthcare Products Regulatory Agency (MHRA) in regulating the use of advanced-therapy medicinal products (ATMPs) in Great...

  • UK MHRA suspends TGN 1412 trial.  // Reactions Weekly;3/25/2006, Issue 1094, p3 

    The article reports on the decision of the British Medicines and Healthcare Products Regulatory Agency to suspend a phase I clinical trial involving TGN 1412, an anti-CD28 monoclonal antibody from TeGenero AG, after several participants were admitted to intensive care after receiving the drug,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics